Compare OLED & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | PCVX |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 8.4B |
| IPO Year | 1996 | 2020 |
| Metric | OLED | PCVX |
|---|---|---|
| Price | $90.89 | $59.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $137.50 | $98.33 |
| AVG Volume (30 Days) | 620.1K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ 9.25 | N/A |
| EPS | ★ 5.08 | N/A |
| Revenue | ★ $650,611,000.00 | N/A |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $10.25 | N/A |
| P/E Ratio | $17.91 | ★ N/A |
| Revenue Growth | ★ 0.45 | N/A |
| 52 Week Low | $86.43 | $28.09 |
| 52 Week High | $163.20 | $65.00 |
| Indicator | OLED | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 60.49 |
| Support Level | N/A | $42.30 |
| Resistance Level | $98.09 | $65.00 |
| Average True Range (ATR) | 3.11 | 2.13 |
| MACD | 0.29 | 0.43 |
| Stochastic Oscillator | 39.02 | 97.51 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.